European Equities Traded in the US as American Depositary Receipts Decline Slightly in Tuesday Trading

MT Newswires Live00:23

European equities traded in the US as American depositary receipts were tracking slightly lower late Tuesday morning, declining 0.17% to 1,877.50 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biopharmaceutical company DBV Technologies (DBVT), which climbed 19% and 13% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and internet browser company Opera (OPRA), which rose 7% and 6% respectively.

The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and brewing company Anheuser-Busch InBev (BUD), which fell 3.9% and 2.8% respectively. They were followed by software firm SAP (SAP) and consumer goods company Unilever (UL), which lost 1.8% and 1.7% respectively.

The gainers from the UK were led by biopharmaceutical companies Akari Therapeutics (AKTX) and NuCana (NCNA), which advanced 7.6% and 3% respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Mereo BioPharma Group (MREO), which increased 1.7% and 1.1% respectively.

The decliners from the UK and Ireland were led by biotech firm Trinity Biotech (TRIB) and alcoholic beverage company Diageo (DEO), which dropped 3.6% and 3.2% respectively. They were followed by biopharmaceutical company Amarin (AMRN) and mining company BHP Group (BHP), which lost 1.7% and 1.6% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment